ELVN Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. (ELVN) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 21% planned / 79% discretionary
Largest single sale: $35.7M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Hohl Benjamin 2 fills | CHIEF FINANCIAL OFFICER | Sell 10b5-1 | 6,018 | $58.58 | $352.6K | 41,424 −12.7% of holding | |
| Collins Helen Louise 2 fills | CHIEF MEDICAL OFFICER | Sell 10b5-1 | 5,000 | $58.59 | $292.9K | 26,100 −16.1% of holding | |
| Derynck Mika K | Director | Sell 10b5-1 | 158,795 | $60.21 | $9.6M | None left | |
| Hohl Benjamin 5 fills | CHIEF FINANCIAL OFFICER | Sell 10b5-1 | 6,018 | $52.64 | $316.8K | 51,748 −10.4% of holding | |
| Collins Helen Louise 5 fills | CHIEF MEDICAL OFFICER | Sell 10b5-1 | 5,000 | $52.67 | $263.4K | 29,769 −14.4% of holding | |
| Kunkel Lori Anne 2 fills | Director | Sell 10b5-1 | 10,000 | $50.49 | $504.9K | 47,773 −17.3% of holding | |
| 4 fills | Sell | 860,123 | $45.36 | $39.0M | 6,601,878 −11.5% of holding | ||
| Hohl Benjamin 3 fills | CHIEF FINANCIAL OFFICER | Sell 10b5-1 | 6,018 | $43.80 | $263.6K | 55,639 −9.8% of holding | |
| Collins Helen Louise 3 fills | CHIEF MEDICAL OFFICER | Sell 10b5-1 | 5,000 | $43.80 | $219.0K | 28,732 −14.8% of holding | |
| 2 fills | Sell | 281,408 | $45.02 | $12.7M | 7,388,902 −3.7% of holding | ||
| Kunkel Lori Anne 3 fills | Director | Sell 10b5-1 | 10,000 | $34.54 | $345.4K | 54,105 −15.6% of holding | |
| Collins Helen Louise 3 fills | CHIEF MEDICAL OFFICER | Sell 10b5-1 | 5,000 | $39.79 | $199.0K | 26,525 −15.9% of holding | |
| Collins Helen Louise 3 fills | CHIEF MEDICAL OFFICER | Sell 10b5-1 | 5,000 | $47.67 | $238.4K | 29,860 −14.3% of holding | |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell 10b5-1 | 40,000 | $35.10 | $1.4M | 25,000 −61.5% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.